HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Fetoscopic Laser Ablation Therapy for Type II Vasa Previa.

AbstractBACKGROUND:
In type II vasa previa, fetoscopic laser ablation has the potential to avoid prolonged hospitalization, elective prematurity, and cesarean delivery associated with traditional conservative management.
OBJECTIVE:
To assess the feasibility and to report perinatal outcomes of type II vasa previa patients treated via fetoscopic laser ablation.
STUDY DESIGN:
This is a retrospective descriptive study of all women with vasa previa treated with laser at our center between 2006 and 2019. After 2010, laser ablation of vasa previa was only offered after 31 gestational weeks. Continuous variables are expressed as means ± SD.
RESULTS:
33 patients were evaluated for laser ablation of suspected vasa previa. Fifteen were not candidates (7 had type I vasa previa and 8 had no vasa previa), and the 18 remaining had type II vasa previa. Ten (56%) elected to undergo in utero laser ablation of the vasa previa vessel(s), which was successful in all patients. The mean gestational age (GA) at the time of the procedure was 28.8 ± 5.4 weeks, and the total operative time was 48.1 ± 21.3 min; there were no perioperative complications. The number of vessels lasered were distributed as follows: 1 (2 cases), 2 (5 cases), and 3 (3 cases). All patients except for 1 were subsequently managed as outpatients. The mean GA at delivery was 35.5 ± 3.2 weeks, and vaginal delivery occurred in 5 cases. The 5 patients with singletons who underwent laser ablation for primary diagnosis of type II vasa previa after the protocol change in 2010 had the following outcomes: mean GA of surgery was 32.5 ± 0.8 weeks, mean GA at delivery was 38.1 ± 1.4 weeks, vaginal delivery occurred in all cases, mean birth weight was 2,965 ± 596 g, and none were admitted to the neonatal intensive care unit.
CONCLUSION:
This cohort represents the largest number of vasa previa cases treated via in utero laser reported to date. Laser occlusion of type II vasa previa was technically achievable in all cases and resulted in favorable outcomes.
AuthorsRamen H Chmait, Valerian Catanzarite, Andrew H Chon, Lisa M Korst, Arlyn Llanes, Joseph G Ouzounian
JournalFetal diagnosis and therapy (Fetal Diagn Ther) Vol. 47 Issue 9 Pg. 682-688 ( 2020) ISSN: 1421-9964 [Electronic] Switzerland
PMID32629451 (Publication Type: Journal Article)
Copyright© 2020 S. Karger AG, Basel.
Topics
  • Adult
  • Delivery, Obstetric
  • Female
  • Fetoscopy (methods)
  • Gestational Age
  • Humans
  • Infant, Newborn
  • Laser Therapy (methods)
  • Pregnancy
  • Retrospective Studies
  • Treatment Outcome
  • Vasa Previa (surgery)
  • Young Adult

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: